Brian Barnett
Psychiatrist and Clinical Researcher
Data updated
Research Footprint
Brian Barnett appears in 10 tracked papers (2018–2024), most studied alongside Psilocybin, LSD and Ketamine, across Depressive Disorders, Anxiety Disorders and Treatment-Resistant Depression (TRD).
Most-cited paper: Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (248 citations).
Frequent co-authors: Peter Hendricks, Rick Doblin and Sanjay Mathew.
Background & Research
Brian S. Barnett is a psychiatrist and clinical researcher whose recent work sits at the intersection of psychedelic-assisted therapies, rapid-acting antidepressant treatments and clinical implementation science. His publications and trial involvement include clinician-survey research characterising American psychiatrists’ attitudes toward classic hallucinogens and follow-up trends over time; translational and policy-orientated reviews on psychedelic-assisted therapy; epidemiological interrogation of long-standing safety claims (for example the alleged link between psychedelic use and cancer); and case-level observations such as a report describing prolonged amelioration of mild red–green colour‑vision deficiency after psilocybin exposure. He has also participated in comparative effectiveness research, including work on ketamine versus electroconvulsive therapy (ECT) for treatment-resistant major depression.
Key Impact
An active contributor to contemporary psychedelic science, Barnett has advanced clinical, epidemiological and implementation-focused work evaluating therapeutic potential, safety signals and real-world translation of psychedelic and rapid-acting treatments for mood disorders.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Brian Barnett is associated with.